

**IN THE SPECIFICATION:**

**Please replace the paragraph beginning at page 1, line 5, with the following rewritten paragraph:**

This application is a divisional application of patent application Serial No. 09/817,144 filed March 27, 2001, which is a divisional application of patent application Serial No. 09/146,755 (now Patent No. 6,242,578 B1) filed September 4, 1998, which is a continuation-in-part of patent application Serial No. 08/198,139 (abandoned) filed February 19, 1994, which are incorporated herein in their entirety by reference thereto.

**Please replace the paragraph beginning at page 2 line 25 with the following rewritten paragraph:**

Figure 3 is a plot of the amount of antimalignin antibody in healthy individuals and individuals presenting with various forms of cancer.

**Please replace the paragraph beginning at page 3, line 4, with the following rewritten paragraph:**

Figures 8A and 8B are bar graphs of the amount of anti-malignin antibody produced *in vivo* upon injection of rabbits with 12-mer synthetic peptide.

**Please replace the paragraph beginning at page 5, line 16, with the following rewritten paragraph:**

In addition, purified antimalignin antibody, because of its demonstrated specificity in fluorescent and other chromogen staining of cell membranes in which the epitopes of malignin have become exposed, is applicable for use alone or as part of a battery of pre-dysplasia or dysplasia-based surrogate endpoint biomarkers in both individual and computerized cytometry.